Jerry D. Morgan

Statistics

Publications

Citations

380

H-Index

Active since

1999

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Merck, S.L.U. (Spain)

United States Military Academy

Jerry D. Morgan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1999–2018

Publications

Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers

Timothy A. Blizzard, Frank DiNinno, Jerry D. Morgan et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 60 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +13

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

Russell Scott, Jerry D. Morgan, Zachary Zimmer et al. · Diabetes Obesity and Metabolism · 2018 · 56 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

Vivian Fonseca, Bart Staels, Jerry D. Morgan et al. · Journal of Diabetes and its Complications · 2012 · 49 citations

Medicine, Pharmacology, Pharmacotherapy +15

Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs

Qiang Tan, Timothy A. Blizzard, Jerry D. Morgan et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 46 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +15

2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs)

Timothy A. Blizzard, Jerry D. Morgan, Ralph T. Mosley et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 36 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +13

1–5 of 11